Pfizer Phase III Lyrica study fails to meet primary efficacy endpoint

Pfizer has reported that Phase III randomized withdrawal design study for Lyrica (pregabalin) in painful diabetic peripheral neuropathy (pDPN) patients has failed to meet its primary efficacy endpoint…
Read the full story: PBR - Clinical Trials News